Media

Angel Pharmaceuticals Completes Nearly RMB 100 Million New Financing Round to Advance Soquelitinib Clinical Development in China

Angel Pharmaceuticals Completes Nearly RMB 100 Million New Financing Round to Advance Soquelitinib Clinical Development in China

2026-06-10

Angel Pharmaceuticals Completes Nearly RMB 100 Mil...

ITK Inhibitor Soquelitinib Combined with CAR-T Therapy Significantly Enhances Antitumor Efficacy

ITK Inhibitor Soquelitinib Combined with CAR-T Therapy Significantly Enhances Antitumor Efficacy

2026-03-18

ITK Inhibitor Soquelitinib Combined with CAR-T The...

Angel Pharmaceuticals Announces Full Initiation of Phase 1b/2 Clinical Trial of Soquelitinib in Atopic Dermatitis in China

Angel Pharmaceuticals Announces Full Initiation of Phase 1b/2 Clinical Trial of Soquelitinib in Atopic Dermatitis in China

2026-01-29

Angel Pharmaceuticals Announces Full Initiation of...

ITK Inhibitor Soquelitinib Shows Promising Clinical Data, Poised to Become the Strongest Competitor to "Immunology Drug King" Dupixent

ITK Inhibitor Soquelitinib Shows Promising Clinical Data, Poised to Become the Strongest Competitor to "Immunology Drug King" Dupixent

2026-01-22

ITK Inhibitor Soquelitinib Shows Promising Clinica...

Angel Pharmaceuticals Announces IND Approval for Phase 1b/2 Clinical Trial of Soquelitinib in Atopic Dermatitis in China

Angel Pharmaceuticals Announces IND Approval for Phase 1b/2 Clinical Trial of Soquelitinib in Atopic Dermatitis in China

2025-06-26

Angel Pharmaceuticals Announces IND Approval for P...

Research Findings on ITK Inhibitor Soquelitinib Published in Nature Partner Journal

Research Findings on ITK Inhibitor Soquelitinib Published in Nature Partner Journal

2024-12-16

Research Findings on ITK Inhibitor Soquelitinib Pu...

2023 Angel Pharmaceuticals Year in Review

2023 Angel Pharmaceuticals Year in Review

2024-02-08

2023 Angel Pharmaceuticals Year in Review

[2023 ASH] Angel Pharmaceuticals Successfully Presents Latest Data from Phase I/Ib Clinical Trial of Soquelitinib (ITK Inhibitor)

[2023 ASH] Angel Pharmaceuticals Successfully Presents Latest Data from Phase I/Ib Clinical Trial of Soquelitinib (ITK Inhibitor)

2023-12-14

[2023 ASH] Angel Pharmaceuticals Successfully Pres...

2023 ASH – Angel Pharmaceuticals to Present Latest Interim Data from Phase I/Ib Clinical Trial of Soquelitinib (ITK Inhibitor) in T-Cell Lymphomas

2023 ASH – Angel Pharmaceuticals to Present Latest Interim Data from Phase I/Ib Clinical Trial of Soquelitinib (ITK Inhibitor) in T-Cell Lymphomas

2023-11-07

2023 ASH – Angel Pharmaceuticals to Present Latest...